Onesource Specialty Pharma

ONESOURCE is trading at ₹1600.00 on 2026-11-06, positioned near the upper end of its recent ranges (+86.4% in the 20-day range). The daily trend is established and bullish, with price holding above all key moving averages (EMA/SMA 20/50) and the Supertrend indicator. ADX at 28.63 confirms moderate trend strength on this horizon. However, a conflicting structure exists on higher timeframes: the monthly trend is bearish (Supertrend down, weak ADX 8.92), and the weekly trend is also bearish despite price being above moving averages. Recent anomalies include extreme volume spikes on 2026-10-27 (+13.8% return, 36x volume ratio) and high participation without clear direction on 2026-10-30. Today’s candlestick formation is a Harami, suggesting potential indecision or consolidation after the recent rally. Risk remains elevated with annualized volatility at +44.1% and a current drawdown of -27.2%. Immediate resistance lies at ₹1627.30 (+1.71%), while support is tight at ₹1598.60 (-0.09%).

Onesource Specialty Pharma (NSE: ONESOURCE) reported strong Q2 FY27 financials, with consolidated revenue rising 37% year-on-year to over ₹5 billion and EBITDA margins expanding to 32%. Management reaffirmed full-year FY28 guidance of $400 million in revenue and $160 million in EBITDA, citing robust demand in semaglutide markets. Operationally, the company has doubled its sterile production capacity by making Line 2 operational, while Line 3 is undergoing qualification for potential commercialization in FY28. Regulatory progress was marked by a USFDA 'Voluntary Action Indicated' (VAI) classification for its Bengaluru Sterile Product Division facility, completing an inspection conducted in June 2026. The company also announced participation in the Jefferies Global Healthcare Conference in London from November 16–19, 2026, where representatives will discuss strategy without sharing unpublished price-sensitive information. Financially, the group recorded a profit after tax of ₹249.97 million for the quarter, though it faced ₹99.27 million in exceptional losses linked to legacy litigation with Prestige Biopharma Limited. Additionally, borrowings were retrospectively reclassified due to an MCA amendment regarding covenant breaches.

OneSource Specialty Pharma reported Q2 FY27 results showing consolidated revenue of ₹4,490.23 million and profit after tax of ₹249.97 million for the quarter ended September 30, 2026. Management cited a 37% year-on-year revenue increase and 53% EBITDA growth with margins expanding to 32%. The company reaffirmed full-year FY28 guidance of $400 million in revenue and $160 million in EBITDA. A significant accounting change involved the retrospective reclassification of ₹3,676.84 million in borrowings from non-current to current liabilities due to an MCA amendment regarding covenant breaches. Additionally, the Group recorded ₹99.27 million in exceptional losses primarily driven by legal charges related to legacy litigation with Prestige Biopharma Limited concerning the Sputnik vaccine contract.

Regulatory progress includes the receipt of a USFDA Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification for its Sterile Product Division facility in Bengaluru, marking the completion of an inspection conducted from June 22 to June 30, 2026. Operational updates confirmed that Line 2 of its Drug Device Combination sterile production capacity is now operational, doubling total sterile production days, while Line 3 has arrived in India and is undergoing qualification for potential commercialization in FY28.

Governance changes include the designation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, subject to shareholder approval. The Board also approved the allotment of 360 equity shares under the ESOP 2021 at an exercise price of ₹278.00 per share, increasing paid-up capital from ₹11,46,73,791 to ₹11,46,74,151. The company will participate in the Jefferies Global Healthcare Conference in London from November 16 to November 19, 2026, discussing publicly available information without sharing unpublished price sensitive information.

Onesource Specialty Pharma demonstrates a sharp operational turnaround in Q2 FY2026-27, with revenue from operations surging to ₹965 crore from ₹449 crore in Q1. This growth is accompanied by improved profitability: net profit rose to ₹82.5 crore (EPS of ₹7.19) compared to ₹25 crore (EPS of ₹2.18) in the prior quarter. However, earnings quality remains under scrutiny as cash flow metrics show divergence; while annual CFO/EBITDA improved to 6.0% in Mar 2026 from -13.0%, the Cash Conversion Cycle deteriorated significantly to 308 days in Mar 2026 from 180 days in Mar 2025, driven by rising Debtor Days (177 days) and Inventory Days (438 days). Balance sheet leverage increased, with borrowings rising to ₹1,755 crore by Sep 2026 and total liabilities growing to ₹2,665 crore. Despite strong sequential sales momentum, long-term returns remain weak, with ROE at -1% for the last year and ROCE dropping to 1.0% in Mar 2026.

Onesource Specialty Pharma faces significant near-term technical headwinds and elevated volatility, as of November 6, 2026. While the daily trend is currently bullish with a closing price of ₹1,600.00, the broader monthly and weekly trends remain bearish, indicating underlying structural weakness. The stock has suffered a maximum drawdown of -49.3% and is currently in a -27.2% drawdown from its peak, reflecting substantial recent losses. Annualized volatility stands at +44.1%, suggesting high price instability for investors. Performance metrics show a challenging backdrop: the stock is down -10.5% year-to-date and -10.8% over the past year, despite short-term gains of +1.1% in the last day and +4.2% over the last month. Immediate resistance lies at ₹1,627.30 (1.71% above), while support is tightly clustered near the pivot at ₹1,598.60. Investors should monitor whether the price can sustainably break above the ₹1,627.30 resistance level to confirm a reversal of the longer-term bearish momentum.